Advent’s Rs 3,150-Crore Yatharth Hospital Deal Tests the Boundaries of India’s Control Regime

Global private equity giant Advent International’s definitive agreement to invest Rs 3,150 crore in Yatharth Hospital & Trauma Care Services has brought India’s corporate takeover regulations back to center stage. By structuring the deal to acquire exactly 24.9% of the listed healthcare chain through its Cyprus-based investment vehicle, Rasmalai Limited, Advent sits a mere 10 basis points below the 25% threshold that automatically triggers a mandatory open offer under Indian securities rules.

The transaction structure has drawn keen attention from corporate lawyers, market analysts, and institutional investors because it tests the subtle line between minority investor protection and legal "control" under both the Securities and Exchange Board of India (SEBI) Substantial Acquisition of Shares and Takeovers (SAST) Regulations and the Competition Commission of India (CCI) framework.

The Architecture of the Deal

Under the terms approved by the board of Yatharth Hospitals, Advent's Rs 3,150-crore primary capital infusion is split across equity and convertible warrants at an issue price of Rs 985.17 per unit:

• Up to 1,30,26,516 fully paid-up equity shares aggregating approximately Rs 1,283.33 crore.
• Up to 1,89,47,664 convertible warrants aggregating approximately Rs 1,866.67 crore, with 25% payable upfront and the remaining 75% due upon exercise.

The structure ensures that on a post-issue fully diluted basis, Advent's holding will stand at 24.87%—rounding to 24.9%—keeping the private equity investor the largest public shareholder. Meanwhile, the founding Tyagi family, who currently hold a 55.8% stake, will remain the single largest shareholder group and continue to guide operations and long-term business strategy.

Why the 24.9% Threshold Matters

Under SEBI’s SAST Regulations, an acquirer acquiring 25% or more of voting rights in a listed Indian entity is statutorily mandated to make an open offer to acquire at least an additional 26% from public shareholders. By pegging the stake at 24.9%, the transaction avoids triggering a compulsory public buyout.

However, the Takeover Code also mandates an open offer if an investor acquires "control," irrespective of whether the shareholding crosses 25%. In Indian securities jurisprudence, determining whether standard private equity covenants—such as affirmative voting items, veto rights over material corporate actions, and board seat entitlements—constitute "protective minority rights" or cross over into "negative control" has historically remained a complex gray area.

Regulators and judicial tribunals like the Securities Appellate Tribunal (SAT) have frequently debated where protective rights end and management control begins. If covenants give an incoming financial sponsor decisive power over commercial policies, management hires, or capital allocation, regulatory authorities can look past the 24.9% equity headline to evaluate the substance of de facto control.

Antitrust and Competition Scrutiny

Beyond SEBI's oversight, Advent has formally approached the Competition Commission of India (CCI) for statutory green-channel clearance. Under the amended Competition Act regime, the definition of control encompasses the ability to exercise "material influence" over the management, affairs, or strategic commercial decisions of an enterprise.

Because Advent maintains active and significant exposures across Indian healthcare and pharmaceuticals—including platforms such as Cohance Lifesciences, Apollo 24/7, Bharat Serums and Vaccines, and Felix Pharma—antitrust authorities evaluate whether substantial cross-platform holdings and governance rights create horizontal or vertical overlaps that could alter competitive dynamics.

War Chest for Hospital Consolidation

For Yatharth Hospitals, the primary equity inflow addresses aggressive regional ambitions. The hospital operator currently manages nine multi-speciality facilities comprising roughly 2,800 beds across Delhi-NCR, Haryana, and Madhya Pradesh, with an announced pipeline reaching 3,250 beds.

Company leadership has indicated that more than 80% of the newly raised funds will be targeted at inorganic acquisitions to expand its network across North India, aiming for a total operational capacity exceeding 5,000 beds over the next three years.

As global private equity giants race to consolidate India’s fragmented healthcare delivery market, how regulatory watchdogs handle Advent's governance covenants and 24.9% position will set an important precedent for structuring minority buyouts across Indian listed entities.

Tags: Advent International Yatharth Hospital SEBI CCI Healthcare Sector Mergers and Acquisitions